E. Im

418 total citations
17 papers, 194 citations indexed

About

E. Im is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, E. Im has authored 17 papers receiving a total of 194 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in E. Im's work include Cancer Genomics and Diagnostics (10 papers), Genetic factors in colorectal cancer (5 papers) and Endometrial and Cervical Cancer Treatments (4 papers). E. Im is often cited by papers focused on Cancer Genomics and Diagnostics (10 papers), Genetic factors in colorectal cancer (5 papers) and Endometrial and Cervical Cancer Treatments (4 papers). E. Im collaborates with scholars based in United States, Spain and Canada. E. Im's co-authors include Ana Oaknin, Kami J. Maddocks, John C. Byrd, Rajat Bannerji, Haiyu Zhou, Jeffrey A. Jones, Amy J. Johnson, Ying Zhu, Lucy Gilbert and Joseph M. Flynn and has published in prestigious journals such as Cancer Research, Annals of Oncology and Leukemia.

In The Last Decade

E. Im

14 papers receiving 190 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Im United States 6 134 53 48 44 44 17 194
Stefanie Schrauwen Belgium 7 97 0.7× 56 1.1× 135 2.8× 43 1.0× 49 1.1× 7 267
Federica Predolini United States 9 148 1.1× 50 0.9× 81 1.7× 46 1.0× 96 2.2× 12 275
Yasuko Oguri Japan 9 74 0.6× 43 0.8× 129 2.7× 16 0.4× 17 0.4× 20 229
Sabine Coppieters United States 4 131 1.0× 18 0.3× 55 1.1× 35 0.8× 14 0.3× 6 185
Ricardo Martínez United States 8 103 0.8× 52 1.0× 141 2.9× 25 0.6× 7 0.2× 15 235
Luca Boscolo Bielo Italy 10 132 1.0× 63 1.2× 58 1.2× 29 0.7× 9 0.2× 27 211
J. Huober Germany 7 218 1.6× 34 0.6× 42 0.9× 87 2.0× 24 0.5× 21 331
Moito Iijima Japan 8 78 0.6× 44 0.8× 152 3.2× 91 2.1× 70 1.6× 18 315
A. DeMichele United States 8 109 0.8× 40 0.8× 31 0.6× 12 0.3× 14 0.3× 39 193
Sherri Damare United States 2 187 1.4× 69 1.3× 59 1.2× 81 1.8× 82 1.9× 2 292

Countries citing papers authored by E. Im

Since Specialization
Citations

This map shows the geographic impact of E. Im's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Im with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Im more than expected).

Fields of papers citing papers by E. Im

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Im. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Im. The network helps show where E. Im may publish in the future.

Co-authorship network of co-authors of E. Im

This figure shows the co-authorship network connecting the top 25 collaborators of E. Im. A scholar is included among the top collaborators of E. Im based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Im. E. Im is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ali, Shabana Amanda, Anna K. Johnson, Maria Beatriz G. VILLANUEVA, et al.. (2025). Complement activation correlates with impaired olfactory function in patients with chronic rhinosinusitis with nasal polyps. Chemical Senses.
2.
Eide, Jacob G., Edward C. Kuan, Nithin D. Adappa, et al.. (2024). Subtotal Middle Turbinate Resection in Patients with Chronic Rhinosinusitis with Nasal Polyps is Unlikely to Cause Empty Nose Syndrome: A Multi‐Institutional Prospective Study. The Laryngoscope. 135(1). 59–65. 1 indexed citations
3.
Im, E., et al.. (2024). Is there an increased risk of otitis media in children with obstructive sleep apnea?. International Journal of Pediatric Otorhinolaryngology. 182. 112014–112014.
4.
Im, E., et al.. (2024). Olfactory Neuroblastoma With Divergent Differentiation: Contemporary Management of Unusual Pathology and Literature Review. Ear Nose & Throat Journal. 1580045028–1580045028. 1 indexed citations
5.
6.
7.
Oaknin, Ana, Lucy Gilbert, Jubilee Brown, et al.. (2021). 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial. Annals of Oncology. 32. S388–S389. 5 indexed citations
8.
Berton, Dominique, Ana Oaknin, Víctor Moreno, et al.. (2021). 991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study. Annals of Oncology. 32. S845–S846. 1 indexed citations
9.
Subramanian, Janakiraman, Vı́ctor Moreno, Joaquim Bosch‐Barrera, et al.. (2020). 1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S886–S887. 7 indexed citations
10.
11.
Oaknin, Ana, Vanessa Samouëlian, Cara Mathews, et al.. (2020). Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer. Gynecologic Oncology. 159. 6–6. 5 indexed citations
12.
13.
14.
Sachdev, Jasgit C., Amita Patnaik, Jody Pelusi, et al.. (2017). Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors. Annals of Oncology. 28. v420–v420. 7 indexed citations
15.
Herbst, Roy S., D.-W. Kim, Enriqueta Felip, et al.. (2015). LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy. Annals of Oncology. 26. ix161–ix161. 1 indexed citations
16.
Flynn, Joseph M., Jeffrey A. Jones, Amy J. Johnson, et al.. (2015). Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 29(7). 1524–1529. 88 indexed citations
17.
Baselga, José, Serafín Morales, Ahmad Awada, et al.. (2013). Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer. Cancer Research. 73(24_Supplement). P2–16. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefanie Schrauwen Breakdown of academic impact, for papers by Federica Predolini Breakdown of academic impact, for papers by Yasuko Oguri Breakdown of academic impact, for papers by Sabine Coppieters Breakdown of academic impact, for papers by Ricardo Martínez Breakdown of academic impact, for papers by Luca Boscolo Bielo Breakdown of academic impact, for papers by J. Huober Breakdown of academic impact, for papers by Moito Iijima Breakdown of academic impact, for papers by A. DeMichele Breakdown of academic impact, for papers by Sherri Damare
Rankless by CCL
2026